Amgen and Janssen Biotech to evaluate combination of Amgen’s Kyprolis and Janssen’s Darzalex in multiple clinical studies in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AMGEN and Janssen Biotech Inc. announced a collaboration to evaluate the combination of Amgen’s Kyprolis (carfilzomib) and Janssen’s Darzalex (daratumumab) in multiple clinical studies in patients with multiple myeloma. Under the agreement, the companies may elect to supply drug only or supply drug and share development costs on a study-by-study basis.The first study initiated as...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login